» Articles » PMID: 31030183

The Plasticity of Mesenchymal Stem Cells in Regulating Surface HLA-I

Overview
Journal iScience
Publisher Cell Press
Date 2019 Apr 29
PMID 31030183
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

A low surface expression level of human leukocyte antigen class I (HLA-I) ensures that the mesenchymal stem cells (MSCs) escape from the allogeneic recipients' immunological surveillance. Here, we discovered that both transcriptional and synthesis levels of HLA-I in MSCs increased continuously after interferon (IFN)-γ treatment, whereas interestingly, their surface HLA-I expression was downregulated after reaching an HLA-I surface expression peak. Microarray data indicated that the post-transcriptional process plays an important role in the downregulation of surface HLA-I. Further studies identified that IFN-γ-treated MSCs accelerated HLA-I endocytosis through a clathrin-independent dynamin-dependent endocytosis pathway. Furthermore, cells that have self-downregulated surface HLA-I expression elicit a weaker immune response than they previously could. Thus uncovering the plasticity of MSCs in the regulation of HLA-I surface expression would reveal insights into the membrane transportation events leading to the maintenance of low surface HLA-I expression, providing more evidence for selecting and optimizing low-immunogenic MSCs to improve the therapeutic efficiency.

Citing Articles

Cell therapies for viral diseases: a new frontier.

Nardo D, Maddox E, Riley J Semin Immunopathol. 2025; 47(1):5.

PMID: 39747475 PMC: 11695571. DOI: 10.1007/s00281-024-01031-8.


The Potential of Mesenchymal Stem/Stromal Cells in Diabetic Wounds and Future Directions for Research and Therapy-Is It Time for Use in Everyday Practice?.

Sienko D, Szablowska-Gadomska I, Nowak-Szwed A, Rudzinski S, Gofron M, Zygmunciak P Int J Mol Sci. 2024; 25(22).

PMID: 39596237 PMC: 11594847. DOI: 10.3390/ijms252212171.


Downregulating human leucocyte antigens on mesenchymal stromal cells by epigenetically repressing a β-microglobulin super-enhancer.

Wang F, Li R, Xu J, Bai X, Wang Y, Chen X Nat Biomed Eng. 2024; 8(12):1682-1699.

PMID: 39433971 DOI: 10.1038/s41551-024-01264-w.


GMP-compliant manufacturing of biologically active cell-derived vesicles produced by extrusion technology.

Lau H, Han D, Park J, Lehner E, Kals C, Arzt C J Extracell Biol. 2024; 1(12):e70.

PMID: 38938599 PMC: 11080851. DOI: 10.1002/jex2.70.


Recent Findings on Therapeutic Cancer Vaccines: An Updated Review.

Sheikhlary S, Lopez D, Moghimi S, Sun B Biomolecules. 2024; 14(4).

PMID: 38672519 PMC: 11048403. DOI: 10.3390/biom14040503.


References
1.
Hematti P . Human embryonic stem cell-derived mesenchymal progenitors: an overview. Methods Mol Biol. 2010; 690:163-74. DOI: 10.1007/978-1-60761-962-8_11. View

2.
Weber J, Rosenberg S . Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res. 1988; 48(20):5818-24. View

3.
Hewitt E . The MHC class I antigen presentation pathway: strategies for viral immune evasion. Immunology. 2003; 110(2):163-9. PMC: 1783040. DOI: 10.1046/j.1365-2567.2003.01738.x. View

4.
Moya A, Larochette N, Paquet J, Deschepper M, Bensidhoum M, Izzo V . Quiescence Preconditioned Human Multipotent Stromal Cells Adopt a Metabolic Profile Favorable for Enhanced Survival under Ischemia. Stem Cells. 2016; 35(1):181-196. DOI: 10.1002/stem.2493. View

5.
Martini M, Testi M, Pasetto M, Picchio M, Innamorati G, Mazzocco M . IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine. 2010; 28(20):3548-57. DOI: 10.1016/j.vaccine.2010.03.007. View